Floatz logo

Monosialotetrahexosylganglioside

Radiotherapy Side Effect

Sun Yat-sen UniversityPhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Radiotherapy Side Effect cohort.

Asset / SponsorPhaseRating
FILGRASTIM
IRCCS San Raffaele
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-sen University
Phase 3BB
ETOPOSIDE
Sun Yat-sen University
Phase 3BB
Amifostine
Alliance for Clinical Trials in Oncology
Phase 3BB
Carboplatin
Sun Yat-sen University
Phase 3BB

View all 37 →

Same molecule, other indications

Monosialotetrahexosylganglioside is also rated in:

breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
cognitive disorderDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →